Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience

Figures & data

Table 1 . Clinical characteristics.

Case	301
Age(years)
Median	27
Range	2–93
Sex(F/M), n(%)	178/123(59%/41%)
Follow-up (months)
Median	38
Range	1–144
Severity of AA, n(%)
NSAA	157(52)
SAA	78(26)
VSAA	66(22)
Primary treatment, n(%)
ATG/ALG + CsA	26(9)*
allo-HSCT	20(7)**
CsA + androgen or CsA alone	233(77)***
No specific therapy	22(7)****
Second-line treatment, n
ATG/ALG + CsA	7
allo-HSCT	2

Note: *rabbit ATG(15), swine ALG(11), allo-HSCT – allogeneic stem cell transplantation; **sib-matched allo-HSCT(12), haploidentical allo-HSCT(8); ***CsA combined with androgen(216), CsA alone(17); ****androgen alone(n = 11), supportive care(11).

Table 2. Uni- and multivariable Cox-regression.

Variable	Univariable Cox-regression			Multivariable Cox-regression
	HR	95% CI	P	HR	95% CI	P
Age
≤35	1			1
36–65	1.842	1.047−3.24	.034	2.004	1.121−3.58	.019
≥66	2.737	1.284−5.832	.09	1.549	0.663−3.62	.312
Severity
NSAA	1			1
SAA	4.764	2.055−11.042	<.001	5.659	2.43−13.177	<.001
VSAA	18.043	8.194−39.729	<.001	24.617	10.759−56.326	<.001
Treatment
ATG/ALG + CsA	1			1
allo-HSCT	1.121	0.339−3.652	.861	1.509	0.457−4.976	.5
CsA + androgen or CsA alone	0.504	0.212−1.201	.122	1.978	0.791−4.951	.145
No specific therapy	2.071	0.752−5.702	.147	6.207	2.024−19.041	.001

Figure 1. Overall survival for all patients.

Figure 2. Overall survival in different age groups: ≤35 years, 36∼65 years, and ≥66 years.

Figure 3. Overall survival according to disease severity at diagnosis (very severe, severe, and non-severe AA).

Figure 4. Overall survival for SAA/VSAA patients according to primary treatment.

Figure 5. Correlation between duration of maintenance treatment and PFS in AA patients after response to primary therapy CsA.

Figure 6. Overall survival for TD-NSAA and non–TD-NSAA patients.